Oligopeptide complex for targeted non-viral gene delivery to adipocytes
Source abstract
Abstract
Commercial anti-obesity drugs acting in the gastrointestinal tract or the central nervous system have been shown to have limited efficacy and severe side effects. Anti-obesity drug development is thus focusing on targeting adipocytes that store excess fat. Here, we show that an adipocyte-targeting fusion-oligopeptide gene carrier consisting of an adipocyte-targeting sequence and 9-arginine (ATS-9R) selectively transfects mature adipocytes by binding to prohibitin. Injection of ATS-9R into obese mice confirmed specific binding of ATS-9R to fat vasculature, internalization and gene expression in adipocytes. We also constructed a short-hairpin RNA (shRNA) for silencing fatty-acid-binding protein 4 (shFABP4), a key lipid chaperone in fatty-acid uptake and lipid storage in adipocytes. Treatment of obese mice with ATS-9R/shFABP4 led to metabolic recovery and body-weight reduction (>20%). The ATS-9R/shFABP4 oligopeptide complex could prove to be a safe therapeutic approach to regress and treat obesity as well as obesity-induced metabolic syndromes.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Adipose Tissue and Metabolism · Virus-based gene therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (31)
Show source-provided references
1. Rosen, E. D. & Spiegelman, B. M. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 444, 847–853 (2006).10.1038/nature05483 ↗
2. Ouchi, N., Parker, J. L., Lugus, J. J. & Walsh, K. Adipokines in inflammation and metabolic disease. Nature Rev. Immunol. 11, 85–97 (2011).10.1038/nri2921 ↗
3. Cinti, S. The adipose organ. Prostaglandins Leukot. Essent. Fatty Acids 73, 9–15 (2005).10.1016/j.plefa.2005.04.010 ↗
4. Elangbam, C. S. Review paper: Current strategies in the development of anti-obesity drugs and their safety concerns. Vet. Pathol. 46, 10–24 (2009).10.1354/vp.46-1-10 ↗
5. Schaffler, A., Scholmerich, J. & Salzberger, B. Adipose tissue as an immunological organ: Toll-like receptors, C1q/TNFs and CTRPs. Trends Immunol. 28, 393–399 (2007).10.1016/j.it.2007.07.003 ↗
6. Ahima, R. S. Central actions of adipocyte hormones. Trends Endocrinol. Metab. 16, 307–313 (2005).10.1016/j.tem.2005.07.010 ↗
7. Cooke, D. & Bloom, S. The obesity pipeline: Current strategies in the development of anti-obesity drugs. Nature Rev. Drug Discov. 5, 919–931 (2006).10.1038/nrd2136 ↗
8. Nawrocki, A. R. & Scherer, P. E. Keynote review: The adipocyte as a drug discovery target. Drug Discov. Today 10, 1219–1230 (2005).10.1016/S1359-6446(05)03569-5 ↗
9. Stenkula, K. G. et al. Human, but not rat, IRS1 targets to the plasma membrane in both human and rat adipocytes. Biochem. Biophys. Res. Commun. 363, 840–845 (2007).10.1016/j.bbrc.2007.09.065 ↗
10. Watanabe, M. et al. Regulation of PPAR gamma transcriptional activity in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 300, 429–436 (2003).10.1016/S0006-291X(02)02860-7 ↗
11. Cao, L. et al. Molecular therapy of obesity and diabetes by a physiological autoregulatory approach. Nature Med. 15, 447–454 (2009).10.1038/nm.1933 ↗
12. Dhillon, H. et al. Central leptin gene therapy suppresses body weight gain, adiposity and serum insulin without affecting food consumption in normal rats: A long-term study. Regul. Pept. 99, 69–77 (2001).10.1016/S0167-0115(01)00237-3 ↗
13. Chen, G. et al. Disappearance of body fat in normal rats induced by adenovirus-mediated leptin gene therapy. Proc. Natl Acad. Sci. USA 93, 14795–14799 (1996).10.1073/pnas.93.25.14795 ↗
14. Won, Y. W., Yoon, S. M., Lee, K. M. & Kim, Y. H. Poly(oligo-D-arginine) with internal disulfide linkages as a cytoplasm-sensitive carrier for siRNA delivery. Mol. Ther. 19, 372–380 (2011).10.1038/mt.2010.242 ↗
15. Won, Y. W., Kim, H. A., Lee, M. & Kim, Y. H. Reducible poly(oligo-D-arginine) for enhanced gene expression in mouse lung by intratracheal injection. Mol. Ther. 18, 734–742 (2010).10.1038/mt.2009.297 ↗
16. Wilson, D. S. et al. Orally delivered thioketal nanoparticles loaded with TNF-alpha-siRNA target inflammation and inhibit gene expression in the intestines. Nature Mater. 9, 923–928 (2010).10.1038/nmat2859 ↗
17. Mok, H., Lee, S. H., Park, J. W. & Park, T. G. Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nature Mater. 9, 272–278 (2010).10.1038/nmat2626 ↗
18. Jeong, J. H., Kim, S. H., Christensen, L. V., Feijen, J. & Kim, S. W. Reducible poly(amido ethylenimine)-based gene delivery system for improved nucleus trafficking of plasmid DNA. Bioconjug. Chem. 21, 296–301 (2010).10.1021/bc9003525 ↗
19. Hyun, H. et al. Therapeutic effects of a reducible poly (oligo-D-arginine) carrier with the heme oxygenase-1 gene in the treatment of hypoxic-ischemic brain injury. Biomaterials 31, 9128–9134 (2010).10.1016/j.biomaterials.2010.08.038 ↗
20. Kolonin, M. G., Saha, P. K., Chan, L., Pasqualini, R. & Arap, W. Reversal of obesity by targeted ablation of adipose tissue. Nature Med. 10, 625–632 (2004).10.1038/nm1048 ↗
21. Mishra, S., Murphy, L. C., Nyomba, B. L. & Murphy, L. J. Prohibitin: A potential target for new therapeutics. Trends Mol. Med. 11, 192–197 (2005).10.1016/j.molmed.2005.02.004 ↗
22. Patel, N. et al. Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells. Proc. Natl Acad. Sci. USA 107, 2503–2508 (2010).10.1073/pnas.0910649107 ↗
23. Sharma, A. & Qadri, A. Vi polysaccharide of Salmonella typhi targets the prohibitin family of molecules in intestinal epithelial cells and suppresses early inflammatory responses. Proc. Natl Acad. Sci. USA 101, 17492–17497 (2004).10.1073/pnas.0407536101 ↗
24. Kim, T. I., Ou, M., Lee, M. & Kim, S. W. Arginine-grafted bioreducible poly(disulfide amine) for gene delivery systems. Biomaterials 30, 658–664 (2009).10.1016/j.biomaterials.2008.10.009 ↗
25. Kumar, P. et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134, 577–586 (2008).10.1016/j.cell.2008.06.034 ↗
26. Furuhashi, M. & Hotamisligil, G. S. Fatty acid-binding proteins: Role in metabolic diseases and potential as drug targets. Nature Rev. Drug Discov. 7, 489–503 (2008).10.1038/nrd2589 ↗
27. Wang, P. et al. Profiling of the secreted proteins during 3T3-L1 adipocyte differentiation leads to the identification of novel adipokines. Cell. Mol. Life Sci. 61, 2405–2417 (2004).
28. Veiseh, O. et al. Cell transcytosing poly-arginine coated magnetic nanovector for safe and effective siRNA delivery. Biomaterials 32, 5717–5725 (2011).10.1016/j.biomaterials.2011.04.039 ↗
29. Ter-Avetisyan, G. et al. Cell entry of arginine-rich peptides is independent of endocytosis. J. Biol. Chem. 284, 3370–3378 (2009).10.1074/jbc.M805550200 ↗
30. Vazquez, E., Ferrer-Miralles, N. & Villaverde, A. Peptide-assisted traffic engineering for nonviral gene therapy. Drug Discov. Today 13, 1067–1074 (2008).10.1016/j.drudis.2008.08.008 ↗
31. Uysal, K. T., Scheja, L., Wiesbrock, S. M., Bonner-Weir, S. & Hotamisligil, G. S. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 141, 3388–3396 (2000).10.1210/endo.141.9.7637 ↗